There are no published observations about adverse effects on the infant whose mother received clomipramine. However, the number of studies in this area is very limited and generally in works which include other tricyclic antidepressants, so no conclusions can be drawn.
Under this low level of observations, possibly would have to conclude that the drug is compatible with breastfeeding, but should be preferred another drug in the same class better known.
The infant whose mother received clomipramine probably received between 1.3 and 2.2% of the administered dose.
Warning of the manufacturer:
Because the active ingredient clomipramine passes into breast milk is not recommended breast feed during treatment with this drug.